Gregory L. Ortega

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network

Anthony A. Meluch, F. Anthony Greco, Howard A. Burris et al. · Journal of Clinical Oncology · 2001 · 210 citations

Medicine, Oncology, Pharmacology +13

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

Moshe Talpaz, Ronald Paquette, Lawrence B. Afrin et al. · Journal of Hematology & Oncology · 2013 · 94 citations · Full text

Medicine, Hematology, Pharmacology +14

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts

Moshe Talpaz, Ronald Paquette, Lawrence B. Afrin et al. · Blood · 2012 · 14 citations

Medicine, Hematology, Pharmacology +12

Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x10⁹/L.

Moshe Talpaz, Solomon I. Hamburg, Katarzyna Jamieson et al. · Journal of Clinical Oncology · 2012 · 11 citations

Medicine, Hematology, Pharmacology +8